Organization
The Karolinska Institute, Stockholm, Sweden
5 abstracts
Abstract
ACHIEVING COMPREHENSIVE DISEASE CONTROL IN LONG-STANDING OR EARLY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ADALIMUMAB PLUS METHOTREXATE VERSUS METHOTREXATE ALONE Org: AbbVie, Leiden University Medical Center, The Karolinska Institute, Stockholm, Sweden, AbbVie Inc., North Chicago, IL, AbbVie Deutschland GmbH & Co KG,
Abstract
A PREDICTION MODEL THAT IDENTIFIES PATIENTS MOST LIKELY TO BENEFIT FROM FIRST-LINE THERAPY WITH ADALIMUMAB PLUS METHOTREXATE IN EARLY RHEUMATOID ARTHRITIS Org: The Karolinska Institute, Stockholm, Sweden, Analysis Group, Inc., Boston, AbbVie Inc., North Chicago, IL, Former employee of AbbVie Inc., North Chicago, United States,
Abstract
BELIMUMAB, A BLYS-SPECIFIC INHIBITOR, REDUCES DISEASE ACTIVITY AND SEVERE FLARES IN SEROPOSITIVE SLE PATIENTS: BLISS-76 STUDY Org: The Karolinska Institute, Stockholm, Sweden, Rheuma Zentrum Favoriten, Vienna, Austria, David Geffen School of Medicine, Cedars-Sinai–UCLA, West Hollywood, CA, United States, Inst of Rheumatology, Prague, Czech Republic, OMRF, Oklahoma City, OK,
Abstract
BASELINE LABORATORY CHARACTERISTICS FROM THE COMBINED PLACEBO GROUPS IN THE BLISS TRIALS ARE PREDICTIVE OF SEVERE FLARE AT 24 WEEKS Org: Johns Hopkins University School of Medicine, Baltimore, United States, The Karolinska Institute, Stockholm, Sweden, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, University of Santo Tomas Hospital, Manila, Philippines, Hospital Clinic, Barcelona, Spain,